Introduction {#sec1-1}
============

Cervical cancer is the second most common cancer, globally. In 2012, more than 8,000 women per 100,000 here in Thailand were diagnosed with cervical cancer and more than half of these cases proved fatal (Bruni et al., 2015). Because of it develops over time, it is one of the preventable types of cancer. The optimal screening test and management for precancerous lesions can reduce morbidity and mortality. Papnicolaou cytology (PAP smear) has been proven to be an effective screening method. It results in the reduction of both the incidence and subsequent mortality. In 2005, the National Health Security Office and Ministry of Public Health (MoPH) of Thailand initiated a comprehensive cervical cancer screening program. Thai women at the ages of 30-60 years are encouraged to undergo a cytology based screening program once every 5 years. In 2006, the program was expanded to include a visual inspection with acetic acid (VIA) screening in certain provinces. National targets for the percentage of women aged 30-60 years who had been screened for cervical cancer once in the previous 5 years were 80% in 2013. The results of the 2010 MoPH survey have shown that 67.4% of women had been screened within the past 5 years (Joseph et al., 2015). Although it appears close to reaching stated targets, there was low screening in some subpopulations. Furthermore, almost half of the women with abnormal tests were lost to follow up. The primary reason that was given for non-attendance was lack of communication. The patient did not receive written information in the form of a letter and those who received their letters did not understand the information provided (Sriamporn et al., 2006). These are limitations of the cytology based screening program. The program requires multiple follow up visits due to its low sensitivity and the high variability of results between laboratories. This program also requires an ample amount of trained cytopathologists and efficient transport and tracking systems.

To improve the effectiveness of this screening program, an appropriate strategy should be developed that not only increases the coverage rates but also increases the detection rates of the disease earlier in the progression. Persistent high risk HPV infection is a cause of cervical cancer. This leads to consideration in determining HR-HPV testing as an alternative screening method. HPV testing has greater sensitivity and fewer false negatives than has been seen in cytology. There is evidence from several large clinical trials that have proved that the benefits of primary screening for HPV can outweigh the potential risks and is superior to standard cytology (Campos et al., 2015; Huh et al., 2015; Jin et al., 2016; Wright et al., 2015). Several countries have now adopted primary screening for HPV in their national screening programs. This study need to evaluate the efficacy of HPV testing as an effective screening test in Thailand.

Materials and Methods {#sec1-2}
=====================

Objective The objective of this study is to compare the efficacy of HPV genotyping test, HR-HPV DNA testing and liquid based cytology methods for the detection of high grade cervical disease.

Study population The model evaluates the outcomes of a hypothetical cohort of 100,000 healthy women 30 to 65 years of age.

Comparison of screening strategies The three primary cervical screening strategies were compared (Figures [1](#F1 F2){ref-type="fig"}-[3](#F3){ref-type="fig"} for detailed algorithms).

![HPV 16/18 Genotyping and Reflex Liquid Based Cytology](APJCP-18-1271-g001){#F1}

![Using hr-HPV Testing alone Every 5 Years Followed by Colposcopy for Women with hr-HPV Positive Results](APJCP-18-1271-g002){#F2}

![Screening by LBC Alone, with Referral of All Women with ASCUS or Worse to Colposcopy](APJCP-18-1271-g003){#F3}

1\. HPV 16/18 genotyping and reflex liquid based cytology

This strategy utilizes HPV testing with genotyping as the primary screening modality. Women who are negative return for routine screening in 5 years. Women who are HPV 16/18 positive are referred for immediate colposcopy. Women positive for other 12 HR-HPV have cytological testing. Cytology with resulting atypical cells of undetermined significance (ASCUS) or worse lead to immediate colposcopy. Women with normal results obtained from cytology are told to return for follow up HPV testing in 12 months.

2\. HR-HPV testing alone followed by a referral for a colposcopy for hr-HPV positive woman.

3\. Cytology based screening followed by a referral for a colposcopy for PAP positive women.

Routine screening is preformed once every 5 years and this is based on clinical guidelines from The National cancer institute of Thailand. Diagnostic conization is considered in strategies 1 and 3 if the results show any discrepancy in the cervical cytology or the colposcopic biopsy. We assume that the loss to follow-up rate for those referred to colposcopy will be at 0%.

Markov Model structure {#sec2-1}
----------------------

We developed a mutually exclusive, state transition testing, Markov chain (Doibilet et al,1985; Sonnerber and Back, 1993) to portray the screening management for the detection of CIN2+ cases using Excel spreadsheet version 15.17 (151206), 2015, Microsoft.

The Natural history model served as the framework within which the effects of each screening strategy were applied and the outcomes compared. Women transitioned annually across 5 possible states; 1) No high risk HPV infection, 2) High Risk HPV infection, 3) Cytology abnormality, 4) CIN2 or 5) condition worsening and fatal. Regression from the CIN 2 to a no CIN state had not occurred. We have modeled health states for pre-cancerous lesions arising from HPV infections. We have not reported on the progression from CIN2 to cancer.

Age-adjusted annual probabilities of death for women without cervical cancer were derived from the general population estimates as reported in the Estimated Generation Life Tables for Thailand of Five-Year Birth Cohorts, 1900-2000 (Prasatkun and Rakchanyaban, 2002).

Model inputs {#sec2-2}
------------

The probabilities for the prevalence of women who are positive for HPV 16/18, women positive for HR-HPV and women cytology positive are a requirement for the model. All of these were taken from the data of National Cancer Institute of Thailand which had enrolled 5056 Thai women, 30-65 years of age, who were undergoing cervical cancer screening. It is the largest trial done to evaluate HPV testing in Thailand. (National Cancer Institute of Thailand, unpublished data 2016)

The incidence of HPV16/18 positive women was 9.3%. The incidence of HR-HPV positive women was approximately 3.5%. The incidence of cytology positive women was 1.5%. The model outcome is the detection rate of CIN2+ for women over 35 years of age and a reduction allowance at an annual rate of 3% ([Table 1](#T1){ref-type="table"}).

###### 

Epidemiological Parameters and Ranges Used in the Sensitivity Analysis

  Prevalence                                                 Rate     Range             Ref
  ---------------------------------------------------------- -------- ----------------- -----
  STRATEGY 1                                                                            
  HPV16/18                                                   0.0093   0.0084 - 0.0279   NCI
  Other 12HR positive                                        0.025    0.0025 - 0.075    NCI
  HPV16/18+ → Colpo CIN2 +                                   0.191                      NCI
  Other 12 HR +ve → LG cyto                                  0.296                      NCI
  Other 12 HR +ve → LG cyto → Colpo CIN2                     0.078                      NCI
  Other 12 HR +ve → NILM → (wait 1y) HPV+ve                  0.25                       †
  Other 12 HR +ve → NILM → (wait 1y) HPV+ve →Colpo CIN2+     0.2                        †
  Other 12 HR +ve → HG cyto                                  0.148                      NCI
  Other 12 HR +ve → HG cyto → Colpo --ve →Conization CIN2+   0.06                       NCI
  Other 12 HR +ve → HG cyto → Colpo CIN2+                    0.15                       NCI
  STRATEGY 2                                                                            
  HR-HPV +ve                                                 0.0346   0.0311 - 0.1038   NCI
  HR-HPV +ve→ Colpo CIN2+                                    0.114                      NCI
  STRATEGY 3                                                                            
  LG cyto +ve                                                0.008    0.0072 - 0.024    NCI
  LG cyto +ve → Colpo CIN2+                                  0.11                       NCI
  HG cyto +ve                                                0.0067   0.00603 - 0.201   NCI
  HG cyto → Colpo CIN2+                                      0.2                        NCI
  HG cyto → Colpo -ve → Conization CIN2+                     0.074                      NCI

\*, Reference form Expert\'s opinion; NCI, National Cancer Institute of Thailand

Model outcome {#sec2-3}
-------------

The model's outcome or dependent variable is the cumulative detection rates of CIN2, CIN3 and cervical cancer cases that had been calculated over a period of 35 years. An annual reduction of 3% is assumed by the Markov model.

Sensitivity analysis {#sec2-4}
--------------------

A one-way sensitivity analysis undertaken to assess the impact of the parameter uncertainty on the model's results followed a standard Monte Carlo approach that had been based on 10,000 randomly generated simulations of parameter values.

Results {#sec1-3}
=======

Throughout the 35 years of cervical screening, the detection rate of CIN2+ using the HPV 16/18 genotype, HR-HPV testing and Liquid base cytology were 1,389, 1,520 and 1,013 cases per 100,000 women, respectively ([Table 2](#T2){ref-type="table"}). The Model prediction indicates that high risk HPV-DNA testing alone was the most effective strategy. Whereas, it has been found that the least effective strategy is the cytology based screening method and this is currently the most common practice utilized in Thailand.

###### 

Outcomes of the Three Cervical Screening Strategies

  Strategy                    Detection rate (per 100,000 women)
  ---------- ---------------- ------------------------------------
  1          HPV16/18         1,389.98
  2          HR-HPV testing   1,520.10
  3          Cytology LBC     1,013.94

The graph in [Figure 4](#F4){ref-type="fig"} shows the comparisons of the detection rates of all three strategies over the 35 year study period. HR-HPV testing alone detected 143 and 510 more cases per 100,000 women than the HPV genotyping test and the cytology-based strategy, respectively. Comparing the HPV genotyping test and cytology-based testing, the HPV genotyping test detected 368 more cases per 100,000 women than did the cytology-based test. In addition, about half of detected cases were missed in screening by the cytology strategy and 10% of the detected cases screened by the HPV genotyping test in comparison to HPV testing alone when the women were tested at the 5 year intervals.

![Comparison the Detection Rate of CIN2+ Cases per 100,000 Women among the Three Strategies](APJCP-18-1271-g004){#F4}

A probabilistic sensitivity analysis (PSA) was conducted to determine how differences in the prevalence of HPV infection and women with positive cytology impact the detection rates of CIN2+. The results suggest that if the incidence of HPV infection increases at least 3 times, HPV genotyping might be the most effective strategy and have also detected approximately 1,200 cases per 100,000 more than in strategy 2. The liquid based cytology method would be more effective if the sensitivity of the cytology was increased ([Table 3](#T3){ref-type="table"}).

###### 

Probabilistic Sensitivity Analysis of the Three Strategies

  Plausible prevalence of                                  Strategy   Detected cases (per 100,000 women)
  ---------------------------------------------- --------- ---------- ------------------------------------
  HPV 16/18 positive women in strategy 1         0.0084    2          1,520
  1                                              1,325                
  3                                              1,013                
  0.0279                                         2         1,520      
  1                                              2,690                
  3                                              1,013                
  Other 12 HR-HPV positive women in strategy 1   0.0225    2          1,520
  1                                              1,311                
  3                                              1,013                
  0.075                                          2         1,520      
  3                                              1,013                
  1                                              2,726                
  HR-HPV positive women in strategy 2            0.03114   2          1,375
  1                                              1,381                
  3                                              1,013                
  0.1038                                         2         4,351      
  1                                              1,381                
  3                                              1,013                
  Low grade cytology positive women              0.0072    2          1,524
  1                                              1,381                
  3                                              979                  
  0.024                                          2         1,524      
  1                                              1,318                
  3                                              1,691                
  High grade cytology positive women             0.00603   2          1,524
  3                                              947.7                
  1                                              1,381                
  0.0201                                         2         1,524      
  1                                              1,381                
  3                                              2,319                

Discussion {#sec1-4}
==========

In this study, HPV based testing is superior than the cytology based strategy for detecting CIN2+ cases. The cytology method has the highest numbers of missed cases. This is in line with several studies that recommend HPV testing to replace cytology as the primary screening method (Campos et al., 2015; Huh et al., 2015; Jin et al., 2016; Kitchener et al.,2014; Wright et al., 2015). In a comparison of HPV genotyping and HPV testing alone, a study has shown that HPV testing alone is more effective than HPV genotyping. Whereas, most previous studies have revealed HPV genotyping as the most effective strategy (Wright et al., 2016; Beal et al., 2014; Huh et al., 2015). This may be explained by many reasons. First, we used the incidence and genotypic distribution of HPV in Thai women which contrasts most studies that have been done in Western countries (Wright et al., 2012; Husain et al., 2015; Kietpeerakool et al., 2015; Kantathavorn et al., 2015). In addition, each step that followed the first screening was different among several studies. Also, the population of the NCI study that has been used as clinical data was small. This may reflect on the impact of the rate of HPV infection and women who were cytology positive.

This is the first study to assess the efficacy of the HPV-based method as a primary screening cervical cancer precursor in Thailand. We used model analysis and conducted sensitivity analysis to represent the actual situations. Furthermore, base case values used in the model were based on the largest amount of and latest data from Thailand. However, there are a few limitations to this study. First, the efficacy we used for comparison is only an intermediate outcome of cervical cancer. Second, clinical input data obtained from a single institute and does not represent the entire population in Thailand. Last, excluding the non compliant cases at follow up, could have possibly over estimated the case numbers.

For a more accurate prediction of the most effective strategy, future studies should be based on the data from multi-centers in several regions of Thailand. Long term clinical outcomes such as lifetime cervical cancer risks or the impact of the women's quality of life should be assessed. It would be helpful if either VIA and Care-HPV tests can be used as comparative algorithms, especially in low resource settings. In policy making plans, economic analysis studies should be evaluated to identify the best strategy.

In conclusion, this study strongly supports the HPV DNA testing as a preferable option to cytology-based screening for detecting cervical cancer. However, the balance between the benefits, burdens and cost of each screening program should be considered.
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